RxDoctor Payments Data

James Hunter, PA

Physician Assistant · Atlanta, GANPI 1336233113

Payments from drug & device makers

$8,401in general payments, 2019–2025

Across 372 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Novartis$723
  • Johnson & Johnson$693
  • Pfizer$665
  • AstraZeneca$612
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$8,11997%
  • Education$2823%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,401 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$70,063
Medicare patients
175
Services billed
2,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab56$470,517
Xeljanz XrTofacitinib Citrate29$167,564
Cosentyx Sensoready (2 Pens)Secukinumab23$160,438
Enbrel SureclickEtanercept19$137,412
HumiraAdalimumab16$121,296
KevzaraSarilumab20$94,249
RinvoqUpadacitinib11$70,124
ProliaDenosumab13$21,358
Hydroxychloroquine Sulfate170$6,930
MethotrexateMethotrexate Sodium217$5,090
Leflunomide71$4,098
Diclofenac Sodium104$3,778
Colchicine32$1,836
Febuxostat19$1,184
Azathioprine15$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Rinvoq$1,428$191,42027 claims
SanofiKevzara$207$94,24920 claims
AmgenProlia$1,418$21,35813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →